Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia

Launched by TURKU UNIVERSITY HOSPITAL · Jun 26, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating advanced ovarian cancer, specifically looking at how certain areas of the tumor that lack oxygen (called hypoxic lesions) respond to treatment. Researchers will use a special imaging technique called 18F-EF5-PET/CT to identify these hypoxic areas within the abdomen. By taking samples from these specific tumor regions, they aim to understand the differences between hypoxic and non-hypoxic tumor tissues and how these differences might affect the cancer's resistance to chemotherapy.

To participate in this study, women aged 18 to 79 who have recently been diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer may be eligible. Participants will undergo imaging and, if selected, surgery to collect tissue samples. This research could provide valuable insights into better treatment strategies for advanced ovarian cancer, especially for those tumors that are more difficult to treat due to low oxygen levels. It’s important to note that participants cannot have a history of other cancers or be pregnant or nursing.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • newly diagnosed advanced epithelial ovarian, primary peritoneal or fallopian tube cancer.
• • age 18-79 years
• • informed concent
• Exclusion Criteria:
• • previous cancer
• • pregnancy or nursing